Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 17c

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.95), $0.17 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $134 million versus the consensus estimate of $129.33 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• BW LPG places $300M convertible bond offering due 2031
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance